Differentiated thyroid cancer (DTC)
Differentiated thyroid cancer and LENVIMA
Getting a diagnosis of differentiated thyroid cancer (DTC) that can no longer be treated with radioactive iodine (RAI) and is progressing can be a shock. If you’ve been diagnosed with DTC, LENVIMA is an FDA-approved prescription treatment that may be an option for you.
LENVIMA was studied in a clinical trial of 392 people with DTC that had progressed and could no longer be treated with RAI.
A clinical study of LENVIMA showed:
59% (154 out of 261 people) of people taking LENVIMA did not have their cancer get worse compared to 14% (18 out of 131 people) on placebo at the time of follow-up
LENVIMA
154 of 261 people
being treated with LENVIMA did not have their cancer get worse
Placebo
18 of 131 people
being treated with a placebo did not have their cancer get worse
was the median* time people treated with LENVIMA did not have their cancer get worse compared to a median of 3.6 months for those taking placebo. That is approximately 5x longer with LENVIMA than with placebo
*Median: The middle number in a list of numbers arranged from lowest to highest.
65% (169 out of 261 people) treated with LENVIMA had their tumors either partially shrink (partial response) or become undetectable (complete response) compared to 2% (2 out of 131 people) of those treated with placebo
169 of 261 people
had their tumors
shrink
LENVIMA
Partial Response: 63%
(165 of 261 people)
Complete Response: 2%
(4 of 261 people)
2 of 131 people
had their tumors
shrink
Placebo
Partial Response: 2%
(2 of 131 people)
Complete Response: 0%
(0 of 131 people)
How does LENVIMA work?
Understanding what LENVIMA is and how it may work can help set expectations for your treatment journey.